{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:22:53Z","timestamp":1761895373248},"reference-count":28,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T00:00:00Z","timestamp":1319760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Aim:\u2002<\/jats:bold> Rheumatoid arthritis (RA) is an important rheumatologic disease in Asia\u2010Pacific countries, as in other parts of the world. However, limited information is available regarding RA therapy in this region. The Asia\u2010Pacific Study in Patients to be Treated With Etanercept or an Alternative Listed DMARD (<jats:italic>AP<\/jats:italic>PEAL) compared efficacy and safety of etanercept (ETN)\u2003+\u2003methotrexate (MTX) versus usual disease\u2010modifying anti\u2010rheumatic drugs (DMARDs)\u2003+\u2003MTX (reflecting regional practice) in subjects with moderate to severe RA from multiple Asia\u2010Pacific countries.<\/jats:p><jats:p><jats:bold>Method:\u2002<\/jats:bold> In this open\u2010label, active\u2010comparator, parallel\u2010design, multicenter study, subjects (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>300) in the Asia\u2010Pacific region were randomized to ETN\u2003+\u2003MTX (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>197) or DMARD\u2003+\u2003MTX (<jats:italic>n\u2003<\/jats:italic>=<jats:italic>\u2003<\/jats:italic>103). The primary efficacy endpoint was the American College of Rheumatology (ACR) response (ACR\u2010N) area under the curve (AUC) over 16\u2003weeks.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> Baseline characteristics were similar between groups. At Week 16, ACR\u2010N AUC indicated a significantly greater response with ETN\u2003+\u2003MTX compared with DMARD\u2003+\u2003MTX (mean difference \u2013145.3; <jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001). Significantly greater proportions of subjects achieved ACR 20, 50 and 70 responses with ETN\u2003+\u2003MTX versus DMARD\u2003+\u2003MTX at Week 16 (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.05). Low Disease Activity Score based on a 28\u2010joint count (DAS28\u2003&lt;\u20033.2) was also achieved by significantly more subjects in the ETN\u2003+\u2003MTX group versus the DMARD\u2003+\u2003MTX group (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.001). Greater improvements were shown for DAS28, pain visual analogue scale, health assessment questionnaire, and physician and patient global assessments (<jats:italic>P\u2003<\/jats:italic>&lt;<jats:italic>\u2003<\/jats:italic>0.05) for ETN\u2003+\u2003MTX versus DMARD\u2003+\u2003MTX. No new safety signals were found.<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> In this Asia\u2010Pacific population of subjects with moderate to severe RA, ETN\u2003+\u2003MTX showed superior efficacy versus usual DMARD\u2003+\u2003MTX regimens, with similar safety profiles.<\/jats:p>","DOI":"10.1111\/j.1756-185x.2011.01680.x","type":"journal-article","created":{"date-parts":[[2011,10,28]],"date-time":"2011-10-28T06:49:11Z","timestamp":1319784551000},"page":"188-196","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Randomized comparison of etanercept with usual therapy in an Asian population with active rheumatoid arthritis: the APPEAL trial"],"prefix":"10.1111","volume":"15","author":[{"given":"Ho\u2010Youn","family":"KIM","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping\u2010Ning","family":"HSU","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merle","family":"BARBA","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wahinnuddin","family":"SULAIMAN","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"ROBERTSON","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bonnie","family":"VLAHOS","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rezaul","family":"KHANDKER","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk","family":"NAB","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce","family":"FREUNDLICH","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"KOENIG","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,10,28]]},"reference":[{"key":"e_1_2_10_2_2","first-page":"31","volume-title":"Epidemiology of the Rheumatic Diseases","author":"Silman AJ","year":"2001"},{"key":"e_1_2_10_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0950-3579(05)80142-6"},{"key":"e_1_2_10_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.23721"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)92442-2"},{"key":"e_1_2_10_6_2","first-page":"238","article-title":"Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132\u2003months of therapy","volume":"25","author":"Weinblatt ME","year":"1998","journal-title":"J Rheumatol"},{"key":"e_1_2_10_7_2","first-page":"589","article-title":"Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one\u2010year prospective study","volume":"13","author":"Spadaro A","year":"1995","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.10.942"},{"key":"e_1_2_10_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780391209"},{"key":"e_1_2_10_10_2","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0889-857X(21)00374-4","article-title":"Management of refractory ankylosing spondylitis and related spondyloarthropathies","volume":"21","author":"Amor B","year":"1995","journal-title":"Rheum Dis Clin North Am"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15640-7"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61000-4"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.044354"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.093294"},{"key":"e_1_2_10_15_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.092254"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1053\/sarh.2001.23704"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707173370301"},{"key":"e_1_2_10_18_2","first-page":"19","article-title":"Consensus statement on the indications and monitoring of anti\u2010tumor necrosis factor (TNF) therapy for rheumatic diseases in Hong Kong (for the working group on the use of TNF inhibitors for the treatment of rheumatic diseases in Hong Kong)","volume":"5","author":"Mok C","year":"2005","journal-title":"Hong Kong Bull Rheum Dis"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780310302"},{"key":"e_1_2_10_20_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780350502"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh297"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780390105"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780380602"},{"key":"e_1_2_10_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2009.146"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21655"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.080791"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(98)09403-3"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1756-185X.2011.01680.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1756-185X.2011.01680.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T06:44:32Z","timestamp":1698734672000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1756-185X.2011.01680.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1756-185X.2011.01680.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1756-185x.2011.01680.x","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"value":"1756-1841","type":"print"},{"value":"1756-185X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,10,28]]},"assertion":[{"value":"2011-10-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}